Literature DB >> 22198777

What an endoscopist should know about immunoglobulin-G4-associated disease of the pancreas and biliary tree.

L Maillette de Buy Wenniger1, E A Rauws, U Beuers.   

Abstract

Autoimmune pancreatitis (AIP) and IgG4-associated cholangitis (IAC) are the recently recognized pancreatobiliary manifestations of IgG4-associated systemic disease (ISD). Clinically, ISD of the pancreas and/or biliary tree may mimic pancreatic cancer, sclerosing cholangitis, or cholangiocarcinoma. Patients often present with abdominal pain, weight loss, jaundice, itch, and biochemical signs of pancreatitis and cholestasis. Tomography may reveal enlargement of the pancreas or may mimic malignant pancreatic lesions, and cholangiopancreatography may disclose irregularities of the pancreatic duct and stenoses of the distal and/or proximal common bile duct and intrahepatic bile ductules. Serum immunoglobulin G4 (IgG4) is elevated in most patients but, unlike tissue IgG4-loaded plasma cell infiltrates, is not diagnostic of the disease. The application of consensus diagnostic criteria for laboratory investigations, imaging, and histologic findings can identify patients who qualify for corticosteroid treatment. The excellent response to immunosuppressive therapy suggests an immune-mediated etiology of the disease, but the exact pathophysiological mechanisms are still under investigation. Relapse may occur after tapering down of corticosteroids, which supports the rationale of maintenance immunosuppression after remission has been induced. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198777     DOI: 10.1055/s-0031-1291540

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  8 in total

Review 1.  IgG4-associated cholangitis: a comprehensive review.

Authors:  Lowiek M Hubers; Lucas J Maillette de Buy Wenniger; Marieke E Doorenspleet; Paul L Klarenbeek; Joanne Verheij; Erik A Rauws; Thomas M van Gulik; Ronald P J Oude Elferink; Stan F J van de Graaf; Niek de Vries; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 2.  IgG4-related diseases of the digestive tract.

Authors:  J-Matthias Löhr; Miroslav Vujasinovic; Jonas Rosendahl; John H Stone; Ulrich Beuers
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-11-08       Impact factor: 46.802

3.  Analysis of the Clinical Course of Primary Sclerosing Cholangitis in Paediatric Population-Single Center Study.

Authors:  Sabina Wiecek; Alicja Wojtyniak; Barbara Pindur; Magdalena Machnikowska-Sokołowska; Katarzyna Gruszczyńska; Urszula Grzybowska-Chlebowczyk
Journal:  Medicina (Kaunas)       Date:  2021-06-27       Impact factor: 2.430

4.  Diagnostic Dilemma in a Patient with Jaundice: How to Differentiate between Autoimmune Pancreatitis, Primary Sclerosing Cholangitis and Pancreas Carcinoma.

Authors:  Matthias Buechter; Christian Georg Klein; Christian Kloeters; Guido Gerken; Ali Canbay; Alisan Kahraman
Journal:  Case Rep Gastroenterol       Date:  2012-04-30

5.  Exposure to occupational antigens might predispose to IgG4-related disease.

Authors:  Lucas J Maillette de Buy Wenniger; Emma L Culver; Ulrich Beuers
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

6.  Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis.

Authors:  Kirsten Boonstra; Emma L Culver; Lucas Maillette de Buy Wenniger; Marianne J van Heerde; Karel J van Erpecum; Alexander C Poen; Karin M J van Nieuwkerk; B W Marcel Spanier; Ben J M Witteman; Hans A R E Tuynman; Nan van Geloven; Henk van Buuren; Roger W Chapman; Eleanor Barnes; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Hepatology       Date:  2014-04-01       Impact factor: 17.425

Review 7.  Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management.

Authors:  Aditi Kumar; Daniel Wheatley; Amar Puttanna
Journal:  Clin Med Insights Gastroenterol       Date:  2016-06-09

Review 8.  Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.

Authors:  Mette Vesterhus; Tom Hemming Karlsen
Journal:  J Gastroenterol       Date:  2020-03-28       Impact factor: 7.527

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.